During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN ). Such investors are advised to ...

Analysts are intrested in these 5 stocks: ( ($BDX) ), ( ($SPOT) ), ( ($ARVN) ), ( ($TWLO) ) and ( ($LUMN) ). Here is a ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Pharmaceuticals industry for Tuesday, May 13, 2025. Let’s take ...

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday ...

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

In 2020, Pfizer paid $1 billion upfront for rights to a protein degrader drug for breast cancer developed by Arvinas, with another $1.4 billion at the back end, and a year earlier Gilead Sciences ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...